Back to top

Hemab Therapeutics Holdings, Inc. (COAG) Receives a Buy from Wedbush

Wedbush analyst David Nierengarten maintained a Buy rating on Hemab Therapeutics Holdings, Inc. yesterday and set a price target of $42.00. The com...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: